But there are different ways of interpreting it
These findings underscore the importance of integrating ferroptosis modulation with joint tissue heterogeneity and the immunometabolic context of OA
PubMed, Ishihara, Junko, et al
It is notable that the absolute value of the HR was in fact similar to that in the SUSTAIN-6 trial
For patients interested in participating in research , the following resources may be helpful: NIHR Be Part of Research (bepartofresearch.nihr.ac.uk) search for Parkinson's and GLP-1 trials Parkinson's UK (www.parkinsons.org.uk) information on current research and trial opportunities When to contact your GP or specialist : If you have Parkinson's disease and diabetes, and wish to discuss whether a GLP-1 receptor agonist is appropriate for your diabetes management If you experience new or worsening symptoms whilst taking any medication If you are interested in clinical trial participationyour neurologist can advise on suitable studies Seek urgent medical attention if you experience: Severe, persistent abdominal pain (possible pancreatitis) Persistent vomiting or inability to keep fluids down (risk of dehydration) Signs of dehydration (extreme thirst, dark urine, dizziness) Allergic reaction (rash, swelling, difficulty breathing) Patients should never start, stop, or modify medications without medical supervision
But as a nutrition coach, here's what I look for when I'm recommending recipes to my clients on these medications: High protein per serving (25g+) to protect muscle mass and keep you satiated longer
